Zealand Pharma A/S (Zealand) (Nasdaq: ZEAL), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced on Tuesday successful results in the confirmatory phase 3 trial with dasiglucagon for severe hypoglycaemia in diabetes.
Dasiglucagon is a potential first-in-class soluble glucagon analog invented and developed by Zealand. It is in development in the ready-to-use HypoPal rescue pen, an auto-injector for easy, fast and effective treatment of severe hypoglycaemia in people with diabetes.
This phase 3 trial confirms that a single dose of dasiglucagon administered via the HypoPal rescue pen rapidly increases blood glucose levels in patients with type 1 diabetes following insulin-induced hypoglycaemia. The company said that 45 subjects were included in the trial, which compared the glycaemic response observed after dosing of dasiglucagon with that of placebo. The primary endpoint was time to plasma glucose recovery.
Overall, no safety concerns were raised for dasiglucagon within the trial.
According to the company, this is the third consecutive phase 3 trial with positive results for dasiglucagon. The previous immunogenicity and pivotal phase 3 trials established dasiglucagon's safety profile and fast onset of action when administered via a pre-filled syringe in adult patients with type 1 diabetes.
The final phase 3 trial that will complete Zealand's NDA application is in paediatric diabetes patients and is still ongoing. Recruitment for this study involving children has proved challenging and results are now expected in September 2019. Accounting for this delay in paediatric patient recruitment, submission of the new drug application (NDA) to the U.S. FDA is now expected early 2020.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes